Leif W. Ellisen, MD, PhD
Dr. Leif W. Ellisen is a practicing oncologist and researcher at the MGH Cancer Center, and an Associate Professor of Medicine at Harvard Medical School. He is also co-Executive Director of the Translational Research Laboratory (TRL) for tumor molecular profiling at the MGH Cancer Center. He received his undergraduate degree from Harvard University, MD and PhD degrees from Stanford University, and completed residency training, oncology fellowship training, and postdoctoral research training at Brigham and Women’s Hospital, the Dana-Farber Cancer Institute, and MGH respectively. Dr. Ellisen is widely published in the field of cancer biology and cancer genetics. His basic research efforts focus on DNA damage response pathways and their link to chemosensitivity in breast and other cancers. His work in the TRL focuses on the clinical application of tumor genetic testing to advance the goal of personalized medicine. He serves on numerous grant review committees and editorial boards, and his work on personalized cancer medicine has been featured in the news media including the Wall Street Journal and the ABC Evening News.